1. Ikatan Dokter Anak Indonesia. Hematologi. IDAI. Jakarta: 2012.

2. Wirawan R. Diagnosis keganasan darah dan sumsum tulang. Dalam: Suryaatmadja, ed.
Pendidikan Berkesinambungan Patologi Klinik. Bagian Patologi Klinik. Jakarta: 2003.

3. Hoffbrand AV, Petit JE, Moss PAH. Kapita Selekta Hematologi 4th ed. ECG. Jakarta: 2005

4. Giler FJ, Cortes JE, Kantarijian HM. Accelerated and blastic phase of chronic myeloid
leukaemia. Hematol Oncol Clini North Am. 2004;18:753.

5. Alwan AF. Acute transformation in chronic myelogenous leukaemia.Tikrit Medical Journal.

2007;13(1):12-17.

6. Rudolph MA, Hoffman JIE, Rudolph CD. Leukemia in rudolphs pediatrics 20th Edition.
McGraw-Hill Professional Publishing:1995. 1269 1278.

7. Parmono B, Sutaryo, Ugrasena IDG, Windiastuti E, Abdulsalam M, Leukemia akut;

kedaruratan onkologi anak dalam buku ajar hematologi. Onkologi Anak: 2010.

8. Anver GF, MaxFJM, Jeanette I. Gambaran klinis diare pada pasien anak leukemia
limfoblastik akut dengan kemoterapi. Jurnal e-Clinic (eCl):2017;5:1.

9. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL
tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic
leukemia with the Philadelphia chromosome. N Engl J Med. Apr 5 2001;344(14):1038-42.

10. Childhood leukemia overview. American Cancer Society.2010.2-14.

11. Lanzkowsky P. Leukemia. In: Lanzkowsky P, editor. Manual of pediatric hematology and
oncology. 5th edition. New York: Elsevier Inc: 2011.518.

12. Harila M. Health related quality of life in survivors of childhood acute lymphoblastic
leukaemia. Oulu: University of Oulu: 2011.

13. Markman M. Chronic Myeloid Leukimia and BCR-ABL. Emedicine: 2009.

14. Belson, Martin, dkk. Risk factors for acute leukimia in children: a review dalam
environmental health perspective. 2007;115(1):138-143.

15. Smith Ma, et al. Leukimia (ICCI 1). SEER pediatric monograph,national cancer institute.
2000.

16. Widiaskara IM, dkk. Luaran pengobatan fase induksi pasien leukimia limfoblastik akut pada
anak di rumah sakit umum dr. soetomo surabaya. Sari pediatri. 2010;12:2.

17. Ikatan Dokter Anak Indonesia. Buku ajar hemato onkologi anak. IDAI. Jakarta. 2006.

18. Schwartz WM. Leukositosis dalam pedoman klinis pediatri. 2005.441-445.

19. Kantarjian HM, Talpaz M. Chronic myelogenous leukemia. Hematol Oncol Clin N Am. Jun
2004;18(3):15-16.

20. Kliegman MR, RE Bhermann, HB Jenson. The leukemias in nelson textbook of pediatrics
18th edition. 2007: 2116 2122.

21. McKenzie SB. Text book of hematology. 2nd edition. Baltimore: William & Wilkins.
2011.309- 417.

22. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. Oct 1
2001;98(7):2039-42.

23. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, et al. Long-term
prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic
myeloid leukemia in chronic phase treated with imatinib. Cancer. Mar 1 2011;117(5):982-91.

24. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with
unrelated donor bone marrow transplantation: results in 102 cases. Blood. Apr 15
1990;75(8):1728-32.

25. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, et al. The effect of
prior exposure to imatinib on transplant-related mortality. Haematologica. Apr
2006;91(4):452-9.